ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,308.15
1.17%
US Tech 100
18,094.80
1.44%
다우존스 지수
39,908.00
0.88%
Bitcoin
65,811.89
6.93%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) 뉴스

INCY

Incyte (INCY)

Incyte Corporation
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:INCY
일자시간출처헤드라인심볼기업
2024/05/1600:44Business WireIncyte présentera les données de son portefeuille d'oncologie lors de la réunion annuelle 2024 de l'ASCO et du congrès EHA2024NASDAQ:INCYIncyte Corporation
2024/05/1600:10Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:INCYIncyte Corporation
2024/05/1506:00Business WireIncyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressNASDAQ:INCYIncyte Corporation
2024/05/1422:05IH Market NewsProducer Price Inflation Data May Weigh On Wall StreetNASDAQ:INCYIncyte Corporation
2024/05/1407:06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:INCYIncyte Corporation
2024/05/1405:34IH Market NewsDow Snaps Eight-Day Winning Streak After Lackluster SessionNASDAQ:INCYIncyte Corporation
2024/05/1400:19Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:INCYIncyte Corporation
2024/05/1320:19Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:INCYIncyte Corporation
2024/05/1320:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
2024/05/1320:00Business WireIncyte Announces Intention to Buy Back up to $2.0 Billion of its Common StockNASDAQ:INCYIncyte Corporation
2024/05/1007:40Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:INCYIncyte Corporation
2024/05/1007:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
2024/05/0221:00Business WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
2024/04/3020:00Business WireIncyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
2024/04/2407:11Business WireIncyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorieNASDAQ:INCYIncyte Corporation
2024/04/2407:01Business WireIncyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekanntNASDAQ:INCYIncyte Corporation
2024/04/2320:00Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsNASDAQ:INCYIncyte Corporation
2024/04/1121:00Business WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
2024/04/0121:30Business WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
2024/03/3005:30Business WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
2024/03/1121:57Business WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
2024/03/1121:57Business WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
2024/03/1119:06Business WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
2024/03/1118:53Business WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
2024/03/1105:05Business WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
2024/03/1105:05Business WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
2024/03/0504:38Business WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
2024/03/0504:02Business WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
2024/03/0422:00Business WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
2024/03/0100:19Business WireIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AINASDAQ:INCYIncyte Corporation
 검색 관련기사 보기:NASDAQ:INCY

최근 히스토리

ASX
CLT
Cellnet
LSE
AI35
Hsbc Bk.25
COIN
RGSTGBP
BIT
Q00136
Leonteq Securities
ASX
SLP
LSE
63SD
Euro.bk. 40
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유